for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novartis AG (ADR)

NVS

Latest Trade

89.51USD

Change

0.00(0.00%)

Volume

178

Today's Range

--

 - 

--

52 Week Range

74.97

 - 

96.31

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
89.51
Open
0.00
Volume
178
3M AVG Volume
36.04
Today's High
--
Today's Low
--
52 Week High
96.31
52 Week Low
74.97
Shares Out (MIL)
2,527.37
Market Cap (MIL)
225,857.60
Forward P/E
17.14
Dividend (Yield %)
3.15

Next Event

Novartis AG at Jefferies London Healthcare Conference

Latest Developments

More

Aspen Pharmacare Sells Japanese Ops To Sandoz For Up To Eur 400 Mln

Sandoz Receives FDA Approval For Oncology Supportive Care Ziextenzo

Novartis Says FDA Placed Partial Hold On Avxs-101 Intrathecal Trials For SMA Patients

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Novartis AG (ADR)

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.

Industry

Major Drugs

Contact Info

Lichtstrasse 35

+41.61.3241111

https://www.novartis.com/

Executive Leadership

Joerg Reinhardt

Independent Non-Executive Chairman of the Board

Alex Krauer

Honorary Chairman of the Board

Daniel L. Vasella

Honorary Chairman of the Board

Vasant Narasimhan

Chief Executive Officer, Member of the Executive Committee

Enrico Vanni

Independent Non-Executive Vice Chairman of the Board

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

48.5K

2017

49.1K

2018

51.9K

2019(E)

47.8K
EPS (USD)

2016

4.710

2017

4.860

2018

5.150

2019(E)

5.242
Price To Earnings (TTM)
28.98
Price To Sales (TTM)
4.56
Price To Book (MRQ)
3.87
Price To Cash Flow (TTM)
17.62
Total Debt To Equity (MRQ)
57.34
LT Debt To Equity (MRQ)
41.57
Return on Investment (TTM)
7.13
Return on Equity (TTM)
5.57

Latest News

Latest News

BRIEF-Novartis Gets Positive CHMP Opinion For Mayzent For Treatment Of Adult Patients With Active SPMS

* NOVARTIS RECEIVES POSITIVE CHMP OPINION FOR MAYZENT® (SIPONIMOD) FOR THE TREATMENT OF ADULT PATIENTS WITH ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS) Source text for Eikon: Further company coverage: (Reporting by Berlin Speed Desk)

BRIEF-Novartis cites positive data for Cosentyx in axial spondyloarthritis

* NEW NOVARTIS PREVENT DATA SHOW COSENTYX DELIVERS EARLY RELIEF IN AXIAL SPONDYLOARTHRITIS

Roche drug for spinal muscular atrophy hits target in late-stage trial

Roche's bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on Monday when the Swiss drugmaker said its drug risdiplam improved motor function in a key study.

Roche sets sights on Novartis, Biogen as SMA trial hits target

Roche's bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on Monday when the Swiss drugmaker said its drug risdiplam improved motor function of patients in a key study.

Novartis buys Aspen's Japanese generic unit for up to 400 million euros

Novartis <NOVN.S> is buying the Japanese generics unit of South Africa's Aspen Pharmacare <APNJ.J> in a deal worth up to 400 million euros ($440.80 million) to expand in the world's third-biggest drug market, the Swiss drugmaker said on Monday.

South Africa's Aspen to sell Japan operations to Novartis unit

Aspen Pharmacare Holdings agreed to sell its Japanese operations to Novartis' Sandoz for up to 400 million euros ($440.80 million) through a unit as it looks to cut debt, the South African drugmaker said on Monday.

Novartis's Sandoz generics unit buying Aspen's Japanese operations

Novartis' Sandoz generic drug unit is buying Aspen's Japanese operations for an initial payment of 300 million euros ($330.60 million) to expand in the world's third-biggest generic medicines market, the Swiss drugmaker said on Monday.

Novartis gets U.S. nod for long-delayed Amgen copycat

Novartis on Tuesday won U.S. approval for its long-delayed version of Amgen's $4 billion seller Neulasta drug, helping the Swiss drugmaker in its uphill battle to sell copies of rivals' blockbusters in the world's top drug market.

Novartis arthritis drug falls short in challenge to global bestseller

Novartis said a trial fell short of producing statistical evidence that its anti-inflammatory drug Cosentyx can beat the world's best-selling drug Humira in treating a type of arthritis.

Novartis arthritis drug fails to prove it is significantly better than rival

A clinical trial of Novartis's Cosentyx drug has failed to prove it is significantly better than a rival treatment for a type of arthritis, the Swiss company said on Friday.

Novartis' Zolgensma study halted by FDA amid safety questions

U.S. regulators have halted a trial of Novartis's Zolgensma treatment after an animal study raised safety concerns, the company said on Wednesday, in a setback for the drugmaker's plan to expand its use to older patients.

BRIEF-Novartis Says FDA Placed Partial Hold On Avxs-101 Intrathecal Trials For SMA Patients

* FDA PLACED A PARTIAL HOLD ON AVXS-101 INTRATHECAL CLINICAL TRIALS FOR SMA PATIENTS BASED ON FINDINGS IN A SMALL PRE-CLINICAL ANIMAL STUDY

BRIEF-Novartis Gets Label Update For Cosentyx Dosing In Ankylosing Spondylitis

* NOVARTIS RECEIVES APPROVAL FOR COSENTYX LABEL UPDATE IN EUROPE TO INCLUDE DOSING FLEXIBILITY IN ANKYLOSING SPONDYLITIS Source text for Eikon: Further company coverage: (Berlin Speed Desk)

BRIEF-Pliant Therapeutics Announces Collaboration With Novartis

* PLIANT THERAPEUTICS ANNOUNCES STRATEGIC COLLABORATION TO DEVELOP NOVEL THERAPIES FOR NASH AND FIBROTIC DISEASES

Novartis data suggest payers getting breaks on gene therapy Zolgensma

Novartis sales data on Tuesday suggested the Swiss drugmaker is reaping less than the $2.1 million U.S. list price for its gene therapy Zolgensma, as insurers may be getting breaks on the world's most-expensive one-time treatment.

Novartis gets lift from $2.1 million gene therapy Zolgensma

Swiss drugmaker Novartis <NOVN.S> boosted its 2019 forecasts on Tuesday after beating third-quarter expectations, a feat helped by the sales debut of gene therapy Zolgensma, the world's most expensive one-time treatment.

BRIEF-Novartis says Zolgensma delay in Europe, Japan due to manufacturing questions from regulators

* SANDOZ Q3 OPERATING INCOME WAS USD 191 MILLION (-47%, -42% CC) IMPACTED BY CHANGES IN LEGAL SETTLEMENT PROVISIONS, HIGHER NET MANUFACTURING AND SANDOZ TRANSFORMATION RESTRUCTURING EXPENSES AND LOWER DIVESTMENT INCOME

Novartis boosts 2019 targets after Q3 beat

Swiss drugmaker Novartis on Tuesday boosted its full-year targets, with sales now expected to grow at a high single-digit percentage rate and core operating income now seen growing at a mid- to high-teen rate.

Novartis gets FDA boost in crowded eye drug market

Novartis's anti-blindness medicine Beovu has become the latest eye drug to win U.S. Food and Drug Administration approval, giving the Swiss drugmaker a boost in the increasingly competitive market for eye problems among an aging population.

Novartis gets U.S. approval for eye drug Beovu

Novartis has received approval from the U.S. Food and Drug Administration for its Beovu drug to treat a cause of vision loss, the Swiss pharmaceuticals company said on Tuesday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up